Price
No data yet.
Social Signal Score
Analyst Ratings
27 analystsRevenue
$12.30B+32.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Belén Garijo López
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 76,493
- Beta
- 0.28
- Country
- FR
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.48
Financials
Revenue
$12.30B+32.3%Net Income
$343.00M-79.5%EBITDA
$1.68B-40.4%Free Cash Flow
$3.90B+8.8%EPS (diluted)
$0.14-78.5%Shares Outstanding (diluted)
2.39B-7.1%Operating Expenses
$4.87BCash & Debt
$6.35BReturn of Capital
$6.92BDividend per Share
$2.42Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.72B | $7.81B | $3.20 |
| 2024 | $44.29B | $5.56B | $2.19 |
| 2023 | $41.62B | $5.40B | $2.15 |
| 2022 | $40.56B | $8.37B | $3.19 |
| 2021 | $39.17B | $6.22B | $2.49 |
| 2020 | $37.37B | $12.29B | $4.91 |
| 2019 | $37.63B | $2.75B | $1.14 |
| 2018 | $35.68B | $4.31B | $1.73 |
| 2017 | $36.22B | $8.42B | $1.50 |
| 2016 | $34.70B | $4.71B | $1.83 |
| 2015 | $34.86B | $4.29B | $1.64 |
| 2014 | $32.00B | $4.39B | $1.67 |
| 2013 | $31.29B | $3.72B | $1.41 |
| 2012 | $35.96B | $4.89B | $1.85 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SNY's reported EPS growth of 4.3% a year over 13 years.
- EPS in 5 years
- $3.95
- Implied price
- $51.36
- Return from $41.23
- 4.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.54 — -38.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -5.7% | -12.2% | -8.6% | -5.5% | -2.8% | -0.3% |
| -0.7% | -7.6% | -3.8% | -0.5% | 2.4% | 5.0% |
| 4.3% | -2.9% | 1.1% | 4.5% | 7.5% | 10.3% |
| 9.3% | 1.7% | 5.9% | 9.5% | 12.7% | 15.5% |
| 14.3% | 6.4% | 10.7% | 14.5% | 17.8% | 20.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (20)
- Newsglobenewswire.com·5h ago·Negative
Press Release : Availability of the aide-mémoire for Q3 2026 results Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
View source ↗ - Newsbusinesswire.com·17h ago·Negative
As First Dupixent MDL Hearing Opens, Weitz & Luxenberg Points to Sanofi's Own Words on a Cancer That Hides Behind Eczema NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the D
View source ↗ - Newszacks.com·3d ago·Positive
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
View source ↗ - Newsseekingalpha.com·4d ago·Neutral
…The deal grants REGN $1B upfront and up to $7B in milestones, with a 50:50 global profit split for new assets, enhancing alignment and commercial potential. REGN and SNY now have several shots on goal to address Dupixent loss-of-exclusivity and emerging long-acting competitors, with key assets potentially launching from 2030 onward.
View source ↗ - Newsmarketbeat.com·4d ago·Positive
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framework for the assets.
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT.
View source ↗ - Newswsj.com·5d ago·Negative
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
View source ↗ - Newsreuters.com·5d ago·Negative
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.
View source ↗ - Newsglobenewswire.com·5d ago·Positive
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 b
View source ↗ - Newsglobenewswire.com·5d ago·Positive
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron
View source ↗ - Newszacks.com·10d ago·Negative
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine Sanofi NASDAQ: SNY is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event.
View source ↗ - Newsmarketbeat.com·16d ago·Negative
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company's executive vice president and head of Specialty Care.
View source ↗ - Newsseekingalpha.com·20d ago·Neutral
Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting the 2026 outlook. Newer launches are scaling faster, giving Sanofi a clearer path toward a more diversified revenue base. The new R&D leadership adds credibility to pipeline prioritization and could improve capital allocation across internal and external innovation.
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines Sanofi and Cheplaphar m to create new strategic partnership i n mature medicines
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.
View source ↗ - Newszacks.com·38d ago·Negative
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell? Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
View source ↗ - Newsfool.com·40d ago·Negative
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside potential ahead for shares of the French pharmaceutical giant.
View source ↗ - Newsseekingalpha.com·42d ago·Neutral
Sanofi: Trump's Vaccine Policy Won't Break The Story On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.
View source ↗ - Newsaccessnewswire.com·49d ago·Neutral
AimwellBio Secures Patented Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors Executed IP assignment brings a decade of technology, published research, and pharma-tested behavioral engagement capabilities into AimwellBio as the Company expands its scientific and medical advisory network MIAMI, FL / ACCESS Newswire / August 17, 2026 / AimwellBio (OTCID:AIMN) today announced the executed assignment of the Trustr intellectual prop
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $1.72 per share
Typical surprise +4.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$1.21 vs $1.10beat
- Thu, Apr 23$1.10 vs $1.06beat
- Thu, Jan 29$0.89 vs $0.84beat
- Fri, Oct 24$1.70 vs $1.60beat
- Thu, Jul 31$0.90 vs $0.96miss
- Thu, Apr 24$0.94 vs $0.90beat
Estimates and results for SNY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (41d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 6, 2024 (2d later)Sell$1,001 - $15,000
- John Jameshouse · MI10 · disclosed Sep 2, 2024 (297d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 6, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (31d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Earl Blumenauerhouse · OR03 · disclosed Jul 6, 2022 (40d later)Buy$15,001 - $50,000
- John Henry Rutherfordhouse · FL04 · disclosed Apr 19, 2022 (34d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Apr 7, 2020 (19d later)Buy$1,001 - $15,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$15,001 - $50,000
- John Henry Rutherfordhouse · FL04 · disclosed Jan 2, 2019 (30d later)Sell$1,001 - $15,000
- John Henry Rutherfordhouse · FL04 · disclosed Aug 20, 2018 (405d later)Buy$1,001 - $15,000
- Patty Murraysenate · WA · disclosed Jun 22, 2017 (7d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.